Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
The Russian company said in a statement that the Commerce Department's decision would not affect its ability to sell its cybersecurity products in the U.S.
Ben Fischer, reporter at Sports Business Journal, speaks to Dave Briggs to unpack everything you need to know about the NFL's Sunday Night Ticket lawsuit.